Pharmacology

posttransplant, transplant, immunosuppressive, drug, treatment, renal, cardiovascular, weight, gain, corticosteroid, obesity, kidney disease, surgery, withdrawal, early, long-termposttransplant, transplant, immunosuppressive, drug, treatment, renal, cardiovascular, weight, gain, corticosteroid, obesity, kidney disease, surgery, withdrawal, early, long-term

posttransplant, transplant, immunosuppressive, drug, treatment, renal, cardiovascular, weight, gain, corticosteroid, obesity, kidney disease, surgery, withdrawal, early, long-termposttransplant, transplant, immunosuppressive, drug, treatment, renal, cardiovascular, weight, gain, corticosteroid, obesity, kidney disease, surgery, withdrawal, early, long-term

posttransplant, transplant, immunosuppressive, drug, treatment, renal, cardiovascular, weight, gain, corticosteroid, obesity, kidney disease, surgery, withdrawal, early, long-termposttransplant, transplant, immunosuppressive, drug, treatment, renal, cardiovascular, weight, gain, corticosteroid, obesity, kidney disease, surgery, withdrawal, early, long-term

recombinant, tissue, plasminogen, activator, acute, ischemic, stroke, emergency, department, rt-PA, intercerebral, hemorrhage, NINDS, National Institute of Neurological Disorders and Stroke trialrecombinant, tissue, plasminogen, activator, acute, ischemic, stroke, emergency, department, rt-PA, intercerebral, hemorrhage, NINDS, National Institute of Neurological Disorders and Stroke trial

recombinant, tissue, plasminogen, activator, acute, ischemic, stroke, emergency, department, rt-PA, intercerebral, hemorrhage, NINDS, National Institute of Neurological Disorders and Stroke trialrecombinant, tissue, plasminogen, activator, acute, ischemic, stroke, emergency, department, rt-PA, intercerebral, hemorrhage, NINDS, National Institute of Neurological Disorders and Stroke trial

recombinant, tissue, plasminogen, activator, acute, ischemic, stroke, emergency, department, rt-PA, intercerebral, hemorrhage, NINDS, National Institute of Neurological Disorders and Stroke trialrecombinant, tissue, plasminogen, activator, acute, ischemic, stroke, emergency, department, rt-PA, intercerebral, hemorrhage, NINDS, National Institute of Neurological Disorders and Stroke trial

short, acting, insulin, analogs, diabetes, type 1, type 2, glycosolated hemoglobin, HBA1c, gestational, glycemic control, regular, long-termshort, acting, insulin, analogs, diabetes, type 1, type 2, glycosolated hemoglobin, HBA1c, gestational, glycemic control, regular, long-term

short, acting, insulin, analogs, diabetes, type 1, type 2, glycosolated hemoglobin, HBA1c, gestational, glycemic control, regular, long-termshort, acting, insulin, analogs, diabetes, type 1, type 2, glycosolated hemoglobin, HBA1c, gestational, glycemic control, regular, long-term

short, acting, insulin, analogs, diabetes, type 1, type 2, glycosolated hemoglobin, HBA1c, gestational, glycemic control, regular, long-termshort, acting, insulin, analogs, diabetes, type 1, type 2, glycosolated hemoglobin, HBA1c, gestational, glycemic control, regular, long-term

megestrol, acetate, elderly, hospital, acquired, malnutrition, appetite, prealbumin, dischargedmegestrol, acetate, elderly, hospital, acquired, malnutrition, appetite, prealbumin, discharged

megestrol, acetate, elderly, hospital, acquired, malnutrition, appetite, prealbumin, dischargedmegestrol, acetate, elderly, hospital, acquired, malnutrition, appetite, prealbumin, discharged

megestrol, acetate, elderly, hospital, acquired, malnutrition, appetite, prealbumin, dischargedmegestrol, acetate, elderly, hospital, acquired, malnutrition, appetite, prealbumin, discharged

thrombocythemia, hemorrhage, thrombosis, arterial, stem, cell, disorder, hydroxyurea, aspirin, anagrelidethrombocythemia, hemorrhage, thrombosis, arterial, stem, cell, disorder, hydroxyurea, aspirin, anagrelide

thrombocythemia, hemorrhage, thrombosis, arterial, stem, cell, disorder, hydroxyurea, aspirin, anagrelidethrombocythemia, hemorrhage, thrombosis, arterial, stem, cell, disorder, hydroxyurea, aspirin, anagrelide

thrombocythemia, hemorrhage, thrombosis, arterial, stem, cell, disorder, hydroxyurea, aspirin, anagrelidethrombocythemia, hemorrhage, thrombosis, arterial, stem, cell, disorder, hydroxyurea, aspirin, anagrelide

cardiovascular disease, fibrates, metabolic syndrome, myocardial infarction, MI, bezafibrate retard, risk, fibric acidcardiovascular disease, fibrates, metabolic syndrome, myocardial infarction, MI, bezafibrate retard, risk, fibric acid

cardiovascular disease, fibrates, metabolic syndrome, myocardial infarction, MI, bezafibrate retard, risk, fibric acidcardiovascular disease, fibrates, metabolic syndrome, myocardial infarction, MI, bezafibrate retard, risk, fibric acid

cardiovascular disease, fibrates, metabolic syndrome, myocardial infarction, MI, bezafibrate retard, risk, fibric acidcardiovascular disease, fibrates, metabolic syndrome, myocardial infarction, MI, bezafibrate retard, risk, fibric acid

respiratory disease, COPD, chronic obstructive pulmonary disease, fluticasone propionate/salmeterol, FSC, ipratropium bromide/albuterol sulfate, IB/ALB, treatmentrespiratory disease, COPD, chronic obstructive pulmonary disease, fluticasone propionate/salmeterol, FSC, ipratropium bromide/albuterol sulfate, IB/ALB, treatment

respiratory disease, COPD, chronic obstructive pulmonary disease, fluticasone propionate/salmeterol, FSC, ipratropium bromide/albuterol sulfate, IB/ALB, treatmentrespiratory disease, COPD, chronic obstructive pulmonary disease, fluticasone propionate/salmeterol, FSC, ipratropium bromide/albuterol sulfate, IB/ALB, treatment

respiratory disease, COPD, chronic obstructive pulmonary disease, fluticasone propionate/salmeterol, FSC, ipratropium bromide/albuterol sulfate, IB/ALB, treatmentrespiratory disease, COPD, chronic obstructive pulmonary disease, fluticasone propionate/salmeterol, FSC, ipratropium bromide/albuterol sulfate, IB/ALB, treatment

cardiovascular diease, warfarin, ethnicity, dosingcardiovascular diease, warfarin, ethnicity, dosing

cardiovascular diease, warfarin, ethnicity, dosingcardiovascular diease, warfarin, ethnicity, dosing

cardiovascular diease, warfarin, ethnicity, dosingcardiovascular diease, warfarin, ethnicity, dosing

urology, nocturia, exercises, behavioral, strategies, bladder dysfunction, incontinence, therapy, oxybutyninurology, nocturia, exercises, behavioral, strategies, bladder dysfunction, incontinence, therapy, oxybutynin

urology, nocturia, exercises, behavioral, strategies, bladder dysfunction, incontinence, therapy, oxybutyninurology, nocturia, exercises, behavioral, strategies, bladder dysfunction, incontinence, therapy, oxybutynin

urology, nocturia, exercises, behavioral, strategies, bladder dysfunction, incontinence, therapy, oxybutyninurology, nocturia, exercises, behavioral, strategies, bladder dysfunction, incontinence, therapy, oxybutynin